Envista Holdings Corporation Stock News

Weakness in China and Russia and lower demand for large capital equipment hurts Envista's (NVST) Q1 revenues.

Envista Holdings Corporation (NYSE:NVST ) Q1 2023 Earnings Conference Call May 3, 2023 5:00 PM ET Company Participants Stephen Keller - VP, IR Amir Aghdaei - President and CEO Howard Yu - CFO Conferen

Envista (NVST) came out with quarterly earnings of $0.38 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.47 per share a year ago.

BREA, Calif. , April 4, 2023 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its first quarter 2023 on Wednesday, May 3, 2023.

The stock price of Envista Holdings Corp. (NYSE: NVST) was a bit of a rollercoaster today. This is what happened.

Envista Holdings Corporation (NYSE:NVST ) Q4 2022 Earnings Conference Call February 8, 2023 5:00 PM ET Company Participants Stephen Keller - Vice President, Investor Relations Amir Aghdaei - President

Envista (NVST) delivered earnings and revenue surprises of 6.12% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

NVST is focused on high growth segments that have a total TAM of $27 billion. NVST has a comprehensive portfolio and global reach to drive sales.

BREA, Calif. , Jan. 12, 2023 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its fourth quarter 2022 on Wednesday, February 8, 2023.

With more than 30 trusted brands, Envista reports that 90% of dentists have some of the company's products in their offices. I expect Envista to grow thanks to the digitization of dental practices glo

Envista Holdings Corporation (NYSE:NVST ) Q3 2022 Earnings Conference Call November 3, 2022 5:00 PM ET Company Participants Stephen Keller - VP-IR Amir Aghdaei - President and CEO Howard Yu - CFO Conf

Envista (NVST) delivered earnings and revenue surprises of 0% and 0.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Upgrades According to Argus Research, the prior rating for AstraZeneca PLC (NASDAQ:AZN) was changed from Hold to Buy. For the second quarter, AstraZeneca had an EPS of $0.86, compared to year-ago quar

Envista Holdings (NYSE:NVST) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 2 0 0 Last 3

Citigroup raised the price target for MacroGenics, Inc. (NASDAQ: MGNX) from $13 to $16. MacroGenics shares rose 4.8% to $3.90 in pre-market trading. Goldman Sachs raised the price target on JinkoSol